Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields.
BACKGROUND
For safety considerations, regulatory agencies recommend the elimination of antibiotic resistance markers and non-essential sequences from plasmid DNA-based gene medicines. In the present study, we analyzed antibiotic-free (AF) vector design criteria impacting upon bacterial production and mammalian transgene expression.


METHODS
Both CMV-HTLV-I R RNA Pol II promoter (protein transgene) and murine U6 RNA Pol III promoter (RNA transgene) vector designs were studied. Plasmid production yield was assessed through inducible fed-batch fermentation. RNA Pol II-directed enhanced green fluorescent protein and RNA Pol III-directed RNA expression were quantified by fluorometry and quantitative real-time polymerase chain reaction, respectively, after transfection of human HEK293 cells.


RESULTS
Sucrose-selectable minimalized protein and therapeutic RNA expression vector designs that combined an RNA-based AF selection with highly productive fermentation manufacturing (>1000 mg/l plasmid DNA) and high-level in vivo expression of encoded products were identified. The AF selectable marker was also successfully applied to convert existing kanamycin-resistant DNA vaccine plasmids gWIZ and pVAX1 into AF vectors, demonstrating a general utility for retrofitting existing vectors. A minimum vector size for high yield plasmid fermentation was identified. A strategy for stable fermentation of plasmid dimers with improved vector potency and fermentation yields up to 1740 mg/l was developed.


CONCLUSIONS
We report the development of potent high yield AF gene medicine expression vectors for protein or RNA (e.g. short hairpin RNA or microRNA) products. These AF expression vectors were optimized to exceed a newly-identified size threshold for high copy plasmid replication and direct higher transgene expression levels than alternative vectors.
Carnes
Aaron E
AE
Nature Technology Corporation, Lincoln, NE, USA.
Luke
Jeremy M
JM
Vincent
Justin M
JM
Anderson
Sheryl
S
Schukar
Angela
A
Hodgson
Clague P
CP
Williams
James A
JA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001483:Base Sequence; D004269:DNA, Bacterial / Q000235:genetics; D005822:Genetic Vectors / Q000235:genetics*; D057809:HEK293 Cells; D015368:Human T-lymphotropic virus 1 / Q000235:genetics; D006801:Humans; D051379:Mice; D012313:RNA / Q000235:genetics*; D012319:RNA Polymerase II / Q000235:genetics* / Q000378:metabolism; D012320:RNA Polymerase III / Q000235:genetics* / Q000378:metabolism; D014162:Transfection; D019076:Transgenes / Q000235:genetics
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D012313:RNA; D012319:RNA Polymerase II; D012320:RNA Polymerase III
Gene Ther. 1999 Aug;6(8):1482-8
10467373
J Gene Med. 2007 May;9(5):392-402
17407167
J Pharm Sci. 2009 Jan;98(1):74-80
18452181
Hum Gene Ther. 2005 Dec;16(12):1404-12
16390271
Nucleic Acids Res. 2007;35(9):e65
17426128
J Gene Med. 2009 May;11(5):444-53
19263463
Biotechnol Adv. 2009 Jul-Aug;27(4):353-70
19233255
J Biotechnol. 2003 Nov 6;105(3):205-13
14580792
J Biotechnol. 2010 Apr 1;146(3):130-7
20138928
J Biol Chem. 1984 Sep 25;259(18):11184-7
6206065
Vaccine. 2006 May 22;24(21):4671-6
16448726
Nucleic Acids Res. 2003 Sep 1;31(17):e100
12930974
Vaccine. 2009 Oct 30;27(46):6454-9
19559109
Nucleic Acids Res. 1997 Jan 15;25(2):449-50
9016578
Nucleic Acids Res. 1998 May 1;26(9):2120-4
9547269
Biotechnol Appl Biochem. 2006 Nov;45(Pt 3):155-66
16819941
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
10829079
Gene Ther. 2001 Mar;8(6):494-7
11313829
J Gene Med. 2010 Apr;12(4):323-32
20209487
Mol Microbiol. 1998 Sep;29(5):1137-45
9767582
Biotechnol J. 2006 Jun;1(6):675-81
16892316
J Bacteriol. 2001 Nov;183(21):6384-93
11591683
Mol Ther. 2004 Sep;10(3):447-55
15336645
Biotechnol Bioeng. 2009 Aug 15;103(6):1129-43
19408315